Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.7410
-0.0484 (-6.13%)
At close: Jun 27, 2025, 4:00 PM
0.7665
+0.0255 (3.44%)
After-hours: Jun 27, 2025, 5:36 PM EDT
Cue Biopharma Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Cue Biopharma stock ranges from a low of $2.00 to a high of $4.00. The average analyst price target of $3.00 forecasts a 304.86% increase in the stock price over the next year.
Price Target: $3.00 (+304.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Cue Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $2 | Buy | Reiterates | $2 | +169.91% | Apr 2, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +439.81% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +169.91% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +304.86% | Jul 26, 2024 |
| Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +979.62% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
8.16M
from 9.29M
Decreased by -12.18%
Revenue Next Year
10.10M
from 8.16M
Increased by 23.84%
EPS This Year
-0.60
from -0.72
EPS Next Year
-0.44
from -0.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2M | 10.5M | 21.5M | ||
| Avg | 8.2M | 10.1M | 20.7M | ||
| Low | 6.3M | 9.8M | 20.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.3% | 28.7% | 113.1% | ||
| Avg | -12.2% | 23.8% | 105.0% | ||
| Low | -32.5% | 20.2% | 98.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.58 | -0.33 | -0.51 | ||
| Avg | -0.60 | -0.44 | -0.49 | ||
| Low | -0.62 | -0.55 | -0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.